RxDoctor Payments Data

Douglas Lowe, MD

Gastroenterology · Milledgeville, GANPI 1194755728

Payments from drug & device makers

$2,620in general payments, 2019–2025

Across 144 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$794
  • Braintree Laboratories, Inc.$337
  • Takeda Pharmaceuticals U.S.A., Inc.$225
  • Merck$222
  • Madrigal Pharmaceuticals$115
  • Medtronic$92
  • plus $834 from 17 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$2,37391%
  • Education$2349%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,620 in reported general payments places this provider in the 40th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$85,391
Medicare patients
313
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide51$54,831
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates94$6,526
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl92$1,591
CholestyramineCholestyramine (With Sugar)15$1,216
Omeprazole108$1,179
Famotidine89$1,149
Pantoprazole Sodium86$663
Ondansetron OdtOndansetron35$662
Promethazine Hcl15$353
Lactulose13$267
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl18$250
ConstuloseLactulose11$122
Ondansetron Hcl11$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$794$54,83151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Milledgeville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →